Funding for this research was provided by:
National Cancer Institute (P30 CA008748)
Received: 6 August 2020
Accepted: 13 October 2020
First Online: 9 November 2020
Compliance with ethical standards
: The study was approved by the MSK Institutional Review Board. Patients provided informed consent for paired tumor-normal DNA and methylation array analysis at the point of care.
: Not applicable.
: A.L. Lin reports receiving commercial research grants from NantOmics and Bristol-Myers Squibb. V. Tabar and/or her immediate family members report receiving commercial research grants from and serving as consultant/advisory board members for BlueRock Therapeutics. N. Moss has consulted for AstraZeneca. I.K. Mellinghoff reports receiving commercial research grants from Amgen, Eli Lilly, and General Electric and is a consultant/advisory board member for Agios Pharmaceuticals, Black Diamond Therapeutics, DC Europa Ltd., Debiopharm Group, Puma Biotechnology, and Voyager Therapeutics. The other authors declare that they have no competing interests.